---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115296"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:21:30.091058+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Q3 loss narrows to $9.0M; YUPELRI sales up 9%; SVP R&D to depart Feb 2024

## Summary
- GAAP net loss from continuing ops $9.0M vs $16.0M prior year; non-GAAP loss $0.7M (improved from $7.1M).
- YUPELRI net sales $58.3M (up 9% YoY, 6% QoQ); implied 35% share $20.4M.
- Richard Graham, SVP R&D, to depart Feb 29, 2024; part-time from Jan 1; Áine Miller promoted to SVP Development.
- Share buybacks $30.8M in Q3; $294.6M total; $30.4M remaining; program expected to complete by year-end 2023.
- PIFR-2 study enrollment complete; top-line data Jan 2024. CYPRESS last patient enrollment H2 2024.

## SEC filing metadata
- accession: 0001104659-23-115296
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/0001104659-23-115296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/tm2330011d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115296
- JSON: https://secwatch.observer/filing/0001104659-23-115296.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115296.txt

## Key facts
- Earnings Releases
  Theravance Biopharma, Inc. reported the third quarter of 2023 results: revenue $15.7 million, net income $9.0 million.
  - Period: the third quarter of 2023
  - Revenue: $15.7 million
  - Net income: $9.0 million
  - Result: reported results
  source text: Total revenue for the third quarter of 2023 was $15.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/0001104659-23-115296-index.htm
- Executive change
  Richard Graham departed as Senior Vice President, Research & Development at Theravance Biopharma, Inc..
  - Action: will be leaving
  - Role: Senior Vice President, Research & Development
  source text: In connection with internal changes at Theravance Biopharma, Inc., Richard Graham, Ph.D., Senior Vice President, Research & Development will be leaving the Company on or around February 29, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/0001104659-23-115296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.